-transparent.png){kind=logo}
The ergoline derivative, Metergoline, in a dosage of 4 to 24 mg/day, was administered for one to eight months to 42 patients with hyperprolactinemic amenorrhea. Mean serum prolactin (PRL) concentrations before treatment were 91.2 ng/mL in the patients with functional hyperprolactinemia (N = 29) and 256.9 ng/mL in the patients with pituitary tumor (N = 13). Within four weeks, Metergoline treatment reduced these PRL concentrations to 39.5 ng/mL and 82.9 ng/mL, respectively. In this study Metergoline treatment resulted in restoration of menstruation in a total of 37 patients; 28 patients ovulated, and eight became pregnant. It is considerably more effective in functional hyperprolactinemia than in hyperprolactinemia caused by adenoma.
H G Bohnet, and
K Kato, and
A S Wolf
January 1982,
Gynecologic and obstetric investigation,
H G Bohnet, and
K Kato, and
A S Wolf
October 1978,
American journal of obstetrics and gynecology,
H G Bohnet, and
K Kato, and
A S Wolf
September 1979,
Fertility and sterility,
H G Bohnet, and
K Kato, and
A S Wolf
January 1997,
Medicina,
H G Bohnet, and
K Kato, and
A S Wolf
August 1977,
The New England journal of medicine,
H G Bohnet, and
K Kato, and
A S Wolf
January 1984,
Clinical and experimental obstetrics & gynecology,
H G Bohnet, and
K Kato, and
A S Wolf
September 1981,
Minerva medica,
H G Bohnet, and
K Kato, and
A S Wolf
November 1978,
Ugeskrift for laeger,
H G Bohnet, and
K Kato, and
A S Wolf
January 1982,
Fertility and sterility,
H G Bohnet, and
K Kato, and
A S Wolf
December 1986,
Fertility and sterility,
